Role of antihypertensive medicines in prostate cancer: a systematic review.
Angiotensin receptor blockers
Angiotensin-converting enzyme inhibitors
Antihypertensive medicines
Calcium channel blockers
Hypertension
Prostate cancer
Renin-angiotensin inhibitors
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
07
11
2023
accepted:
02
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
29
4
2024
Statut:
epublish
Résumé
Hypertension is associated with the risk of prostate cancer (PCa) and its progression, however, it remains unclear whether antihypertensive medicines alter PCa risk or prognosis. This systematic review evaluated the role of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors in the risk and prognosis of PCa. This review was performed in line with PRISMA 2020 guidelines. Eligible studies comprised peer-reviewed observational studies which reported the role of CCBs and RAS inhibitors in PCa, had accessible full texts, and were written in English. Using a combination of keywords, 5 electronic bibliographic databases which included Web of Science, EMBASE, PubMed, Google Scholar and Scopus were searched. A total of 1,346 studies were retrieved and 18 met the inclusion criteria. Thirteen studies reported reduced or no associated risk, improved prognosis, and survival with the use of RAS inhibitors. Studies on CCBs showed evidence of associated risk of PCa. Data extraction from retrieved studies focused on included study characteristics, setting, authors, year, outcomes of interest, and risk ratios. The quality assessment of included studies by the National Heart, Lung, and Blood Institute study assessment tools, showed that all studies had good quality. The use of RAS inhibitors was mostly associated with lower risks or improved prognosis of PCa. CCBs may also be associated with risks of PCa. This suggests that high-risk patients managed with CCBs should be actively monitored for PCa. However, there is need for further evidence from large-scale prospective, controlled cohort studies to determine any influence of CCBs on PCa.
Sections du résumé
BACKGROUND
BACKGROUND
Hypertension is associated with the risk of prostate cancer (PCa) and its progression, however, it remains unclear whether antihypertensive medicines alter PCa risk or prognosis. This systematic review evaluated the role of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors in the risk and prognosis of PCa. This review was performed in line with PRISMA 2020 guidelines.
METHODS
METHODS
Eligible studies comprised peer-reviewed observational studies which reported the role of CCBs and RAS inhibitors in PCa, had accessible full texts, and were written in English. Using a combination of keywords, 5 electronic bibliographic databases which included Web of Science, EMBASE, PubMed, Google Scholar and Scopus were searched.
RESULTS
RESULTS
A total of 1,346 studies were retrieved and 18 met the inclusion criteria. Thirteen studies reported reduced or no associated risk, improved prognosis, and survival with the use of RAS inhibitors. Studies on CCBs showed evidence of associated risk of PCa. Data extraction from retrieved studies focused on included study characteristics, setting, authors, year, outcomes of interest, and risk ratios. The quality assessment of included studies by the National Heart, Lung, and Blood Institute study assessment tools, showed that all studies had good quality.
CONCLUSIONS
CONCLUSIONS
The use of RAS inhibitors was mostly associated with lower risks or improved prognosis of PCa. CCBs may also be associated with risks of PCa. This suggests that high-risk patients managed with CCBs should be actively monitored for PCa. However, there is need for further evidence from large-scale prospective, controlled cohort studies to determine any influence of CCBs on PCa.
Identifiants
pubmed: 38684963
doi: 10.1186/s12885-024-12218-5
pii: 10.1186/s12885-024-12218-5
doi:
Substances chimiques
Antihypertensive Agents
0
Calcium Channel Blockers
0
Angiotensin Receptor Antagonists
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
542Informations de copyright
© 2024. The Author(s).
Références
BMJ Open. 2016 Jun 10;6(6):e010903
pubmed: 27288377
PLoS One. 2018 Jan 16;13(1):e0190443
pubmed: 29338025
Int J Cancer. 2019 Feb 1;144(3):440-447
pubmed: 30110124
Cancer Med. 2016 Jun;5(6):1307-18
pubmed: 26923095
Sci Rep. 2016 Aug 11;6:31358
pubmed: 27511796
Mol Cancer Ther. 2003 Nov;2(11):1139-47
pubmed: 14617787
Anticancer Res. 2018 Jan;38(1):45-49
pubmed: 29277755
PLoS One. 2020 Jun 29;15(6):e0234269
pubmed: 32598349
Ann Epidemiol. 2001 Nov;11(8):534-42
pubmed: 11709272
Cancer Manag Res. 2020 Mar 13;12:1913-1927
pubmed: 32214849
Eur Urol. 2012 Mar;61(3):560-70
pubmed: 22119157
Pharmacotherapy. 2019 Jun;39(6):690-696
pubmed: 30917404
Sci Transl Med. 2017 Oct 4;9(410):
pubmed: 28978752
Prostate. 2017 Feb;77(3):282-290
pubmed: 27753122
BMC Urol. 2018 Mar 7;18(1):17
pubmed: 29514670
J Clin Invest. 1996 Aug 1;98(3):671-9
pubmed: 8698858
Scand J Urol. 2018 Oct - Dec;52(5-6):321-327
pubmed: 30698056
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2502-11
pubmed: 25150047
Open Med. 2009;3(3):e123-30
pubmed: 21603045
Asian J Androl. 2018 Jan-Feb;20(1):37-42
pubmed: 28857052
Urol Oncol. 2014 Jul;32(5):524-36
pubmed: 24054868
Oncol Lett. 2017 May;13(5):3579-3585
pubmed: 28529582
Cancer Lett. 2018 Oct 10;434:120-129
pubmed: 30031758
J Clin Pharm Ther. 2018 Aug;43(4):519-529
pubmed: 29656432
Syst Rev. 2021 Mar 29;10(1):89
pubmed: 33781348
Oncotarget. 2016 Feb 9;7(6):6765-73
pubmed: 26760503
Cancer Causes Control. 2011 Oct;22(10):1445-52
pubmed: 21769492
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):255-9
pubmed: 14973089
J Clin Hypertens (Greenwich). 2021 Apr;23(4):879-887
pubmed: 33492766
Cell Mol Biol (Noisy-le-grand). 2016 Jan 11;62(1):30-3
pubmed: 26828983
Prostate. 2004 Jan 1;58(1):50-6
pubmed: 14673952
J Clin Pharmacol. 2013 Jul;53(7):773-8
pubmed: 23686462
Cancer Causes Control. 2009 Jul;20(5):671-9
pubmed: 19067188
BMJ. 2012 Apr 24;344:e2697
pubmed: 22531797
Sci Rep. 2018 Oct 25;8(1):15772
pubmed: 30361641
Medicina (Kaunas). 2016;52(2):89-98
pubmed: 27170481
Cancer. 2012 Dec 15;118(24):6199-206
pubmed: 23090855
Int J Cardiol. 2015 Aug 15;193:1-7
pubmed: 26002406
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am Fam Physician. 2014 Oct 1;90(7):503-4
pubmed: 25369633
Prostate. 2013 Jun;73(8):865-72
pubmed: 23280547
Front Oncol. 2021 Apr 01;11:664741
pubmed: 33869068
Cancer Causes Control. 2004 Aug;15(6):535-41
pubmed: 15280632
Cancer. 2001 Nov 1;92(9):2462-70
pubmed: 11745304